Overview

DTIC-Dome was a prescription medication approved by the U.S. Food and Drug Administration (FDA) for treating Hodgkin lymphoma. DTIC-Dome was often combined with other drugs such as doxorubicin, bleomycin, and vinblastine sulfate in a chemotherapy regimen. DTIC-Dome was also known by its drug name, dacarbazine.

DTIC-Dome was an anticancer drug and a member of a class of drugs called alkylating agents. DTIC-Dome was believed to work by preventing the production of DNA in cells, thereby blocking cell division.

How was it taken?

DTIC-Dome was administered as an intravenous infusion during chemotherapy treatment.

Side effects

The FDA-approved label for DTIC-Dome listed common side effects including flu-like symptoms, nausea, vomiting, numbness or tingling in the extremities, loss of appetite, low blood cell counts, and pain or irritation at infusion site during infusion.

Rare but serious side effects listed for DTIC-Dome included fetal harm in pregnant people and an increased risk for developing other cancers.

For more details about this treatment, visit:

DTIC-Dome — Drugs.com